Eli Lilly has completed the acquisition of Centessa Pharmaceuticals, gaining access to Centessa's clinical-stage orexin receptor 2 agonists for treating narcolepsy and other sleep disorders. This move enhances Lilly’s pipeline with promising treatments that target the fundamental mechanisms affecting wakefulness and sleep stability, addressing significant unmet medical needs in neurological conditions.
Read the full article at Sleep Review
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





